Article
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2012
Punnoose Elizabeth A, Atwal Siminder, Liu Weiqun, Raja Rajiv, Fine Bernard M, Hughes Brett G M, Hicks Rodney J, Hampton Garret M, Amler Lukas C, Pirzkall Andrea, Lackner Mark R
Abstract excerpt
PURPOSE: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using the CellSearch platform, as well as mutation detection in circulating tumor DNA (ctDNA), in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.